Major Depressive Disorder

Patients with severe mental health issues often are linked to health inequalities that contribute to a shorter life expectancy than the general population.

Developed by BrainsWay, the new device has been shown to decrease anxiety symptoms in adult patients with anxious depression.

There has been a lot of variance in mental health studies during the COVID-19 pandemic.

Higher depressive and manic (symptoms were associated with lower GAF, most strongly among the older participants.

Severe mental disorders had the highest odds ratios for the risk of mortality.

For only reward learning, anhedonia was associated with model-derived learning parameters and neural learning signals.

Younger age and individuals who work more than 41 hours per week were associated with more prevalent mental health symptoms.

Dr. Robert Baillieu discusses how the COVID-19 pandemic has specifically impacted patients dealing with addiction problems.

The treatment was well-tolerated with a safety profile consistent with previous clinical trials.

Lamotrigine is currently being used as a maintenance therapy for bipolar disorder.

Baseline eGFR and increasing age were good predictors of eGFR.

REL-1017 was more effective when administered earlier rather than later.

The higher levels of visits were mostly maintained throughout the pandemic.

The reduction in heavy drinking in individuals between 18-25 years old is likely due to government restrictions on social gatherings.

Closing thoughts regarding a discussion on improving the management of patients with treatment-resistant depression using newer treatment approaches in a more standardized fashion.

Insight regarding proper timing to initiate electroconvulsive therapy to help manage depression.

New research sheds light on the relationship between sleep timing and the risk of developing major depressive disorder (MDD).

Dr Patricia Ares-Romero highlights the traditional classes of antidepressant therapies available, reacts to common treatment-related adverse events, and describes when each type of therapy is most appropriate within a patient’s treatment course.

The appropriateness for initiating psychotherapy, either alone or in combination with other therapies, as frontline treatment for depression.

Recommendations that can help clinicians navigate through the reimbursement process and best support patients who receive intranasal esketamine for treatment-resistant depression.

Additional variables that require consideration if treating appropriate patients with treatment-resistant depression with intranasal esketamine within certified treatment facilities.

Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.

Best practices that can be applied when working with patients and training staff on proper ways to administer intranasal esketamine therapy for treatment-resistant depression in a supervised medical setting.

The purpose and impact of the REMS program established to support the integration of intranasal esketamine into clinics that manage treatment-resistant depression.

Practical experience regarding the timing and response to intranasal esketamine therapy for treatment-resistant depression.